ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2025
Longitudinal changes in white matter hyperintensity volume accelerate across the Alzheimer's continuum in adults with Down syndrome.
Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Multiomics and proteomic insights into Alzheimer's disease biology in Down syndrome.Expert review of neurotherapeutics · 2026Review
- Voxelwise correlation of neighbors as a hypothesis driven framework for characterizing white matter lesion heterogeneity.Scientific reports · 2026Article
- Spatial coupling of enlarged perivascular spaces and white matter lesions across the Alzheimer's disease continuum.Frontiers in neuroscience · 2026Article
- Longitudinal changes in white matter hyperintensity volume accelerate across the Alzheimer's continuum in adults with Down syndrome.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Comprehensive and stratified meta-analysis of diffusion tensor image analysis along the perivascular space in Alzheimer's disease: Linking glymphatic dysfunction with cognitive decline and amyloid pathology.Journal of Alzheimer's disease reportsReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
introductionCerebrovascular disease is elevated across the Alzheimer's disease (AD) continuum in adults with Down syndrome (DS), but regional change within individuals is unknown.
methodsParticipants from the Alzheimer's Biomarker Consortium-Down Syndrome (ABC-DS) study (n = 187) had magnetic resonance imaging (MRI) scans quantified for white matter hyperintensity (WMH) volume. Annualized WMH change was assessed across cognitive diagnostic groups defined by progression or stability between two visits (78% remained cognitively stable (CS), 6% progressed from CS to mild cognitive impairment [MCI]-DS, 5% remained MCI-DS, 6% progressed from MCI-DS to AD, 4% remained AD).
resultsCompared to those who remained CS, WMH changes, particularly in posterior regions, over time were faster in advanced diagnostic groups (i.e., MCI-DS to AD, AD at both timepoints). Monotonic increase across progressive diagnostic groups suggest an acceleration in WMH over time.
conclusionPosterior WMH accelerates with AD progression in adults with DS beginning at the progression from MCI-DS to AD. HIGHLIGHTS: White matter hyperintensity (WMH) volume increased and decreased over time in adults with Down syndrome. WMH decreased over time in the cognitively stable group. WMH increased over time in advanced Alzheimer's disease diagnostic groups. Change in posterior WMH accelerated across progressive Alzheimer's disease groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.